An Open-Label, Multi-Center Phase 1/2 study of Surufatinib in Combination with Gemcitabine in Pediatric Patients with Recurrent or Refractory Solid Tumors COG ADVL2121

Grant

Awarded By

Total Award Amount

  • 57400.00

    • Direct Costs

  • 42206.00

    • Sponsor Award Id

    • Contributor

  • Aman Wadhwa   Investigator  
  • Ana Xavier   Investigator  
  • Elizabeth Alva   Investigator  
  • Emily Johnston   Investigator  
  • Jamie Aye   Principal Investigator  
  • Julie Wolfson-Stockman M.D.   Investigator  
  • Kimberly Whelan M.D.   Investigator  
  • Matthew Kutny M.D.   Investigator